Analyzing...
Loading company...
Nothing flagged for monitoring
“Operates in Pharmaceuticals — Formulations & API.”
₹7,234 Cr revenue.
COGS 32.0%, employees 31.3%.
| KPI | Company | Sector Median |
|---|---|---|
| ROE | 6.6%▼ | 10.5% |
| ROCE | 7.5%▼ | 13.8% |
| Net Margin | 5.4%▼ | 8.7% |
| EBITDA Margin | 16.0% | 16.0% |
| Debt To Equity | 0.39x▲ | 0.21x |
| Rev Growth 3yr | 5.9%▲ | 5.8% |
| EPS Growth 3yr | 26.6%▲ | 3.6% |
Historical valuation data not available.
No related party data available for this company.
This section will be populated when data becomes available.
Disclaimer · The Stock Filter is an information platform, not a SEBI-registered investment adviser. All data, scores, and narratives are generated from public filings and AI analysis — they do not constitute investment advice, recommendations, or endorsements. Always consult a qualified financial adviser before making investment decisions. Past performance does not guarantee future results.
| (₹ Cr) | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹7,918 Cr +9.5% | ₹7,235 Cr +979.3% | ₹670 Cr -89.3% | ₹6,282 Cr +3.7% | ₹6,059 Cr -0.6% | ₹6,099 Cr -33.4% | ₹9,154 Cr +0.5% | ₹9,111 Cr |
| Other Income | ₹54 Cr -4.6% | ₹57 Cr +726.8% | ₹7 Cr -82.1% | ₹38 Cr -53.4% | ₹82 Cr +366.4% | ₹18 Cr -62.8% | ₹47 Cr +32.7% | ₹36 Cr |
| Total Income | ₹7,973 Cr +9.3% | ₹7,291 Cr +976.7% | ₹677 Cr -89.3% | ₹6,320 Cr +2.9% | ₹6,141 Cr +0.4% | ₹6,116 Cr -33.5% | ₹9,202 Cr +0.6% | ₹9,147 Cr |
| COGS | ₹2,557 Cr +10.4% | ₹2,317 Cr +982.4% | ₹214 Cr -88.6% | ₹1,878 Cr +26.2% | ₹1,488 Cr -3.1% | ₹1,536 Cr -51.1% | ₹3,141 Cr -10.8% | ₹3,522 Cr |
| ₹7,279 Cr +9.1% | ₹6,670 Cr +933.1% | ₹646 Cr -89.7% | ₹6,248 Cr +13.6% | ₹5,501 Cr +5.1% | ₹5,235 Cr -34.2% | ₹7,957 Cr -0.1% | ₹7,963 Cr | |
| Profit Before Tax | ₹645 Cr -34.3% | ₹981 Cr | ₹15 Cr -5.7% | ₹16 Cr -97.6% | ₹640 Cr -25.5% | ₹860 Cr -29.0% | ₹1,211 Cr +33.9% | ₹904 Cr |
| Exceptional Items | (₹49 Cr) ↓ Decline | ₹360 Cr ↑ Recovery | (₹17 Cr) +70.3% | (₹57 Cr) | ₹0.00 Cr +100.0% | (₹21 Cr) +38.7% | (₹35 Cr) +87.6% | (₹280 Cr) |
| ₹215 Cr +48.7% | ₹144 Cr | ₹10 Cr -89.4% | ₹93 Cr -57.4% | ₹217 Cr -26.8% | ₹297 Cr -4.8% | ₹312 Cr -4.4% | ₹327 Cr | |
| Net Profit | ₹430 Cr -48.6% | ₹836 Cr | ₹7 Cr ↑ Recovery | (₹65 Cr) ↓ Decline | ₹413 Cr -50.6% | ₹836 Cr -7.0% | ₹898 Cr +55.7% | ₹577 Cr |
| Profit (Owners) | ₹433 Cr -48.5% | ₹839 Cr | ₹8 Cr ↑ Recovery | (₹61 Cr) ↓ Decline | ₹414 Cr -50.5% | ₹836 Cr -6.9% | ₹898 Cr +56.4% | ₹574 Cr |
| Minority Interest | (₹3 Cr) -3.2% | (₹3 Cr) -604.5% | (₹0.44 Cr) +88.7% | (₹4 Cr) -323.9% | (₹0.92 Cr) -253.8% | (₹0.26 Cr) | ₹0.00 Cr -100.0% | ₹3 Cr |
| Other Comprehensive Income | ₹259 Cr +205.1% | ₹85 Cr | ₹5 Cr -97.5% | ₹220 Cr -9.6% | ₹244 Cr +40.0% | ₹174 Cr +426.3% | ₹33 Cr ↑ Recovery | (₹14 Cr) |
| EPS | ₹27.16 | ₹52.70 | ₹0.48 | (₹3.83) | ₹25.99 | ₹52.48 | ₹56.39 | ₹36.07 |
| Diluted Shares | ₹16 Cr | ₹16 Cr | ₹16 Cr | ₹16 Cr | ₹16 Cr | ₹16 Cr | ₹16 Cr | ₹16 Cr |
| Profit Or Loss Of Associates | (₹0.40 Cr) +20.0% | (₹0.50 Cr) ↓ Decline | ₹2 Cr -80.3% | ₹12 Cr ↑ Recovery | (₹10 Cr) ↓ Decline | ₹11 Cr | ₹0.00 Cr | ₹0.00 Cr |
Jubilant Pharmova Limited has informed the Exchange about Copy of Newspaper Publication
Jubilant Pharmova Limited has informed the Exchange regarding Appointment of Mr. Arjun Shanker Bhartia as Joint Managing Director of the company w.e.f. Jun 01, 2026.
Jubilant Pharmova Limited has informed the Exchange regarding Resignation of Mr. Arun Kumar Sharma as Chief Financial Officer of the company w.e.f. May 22, 2026.
Jubilant Pharmova Limited has informed the Exchange regarding a press release dated May 22, 2026, titled "Press Release".
Jubilant Pharmova Limited has informed the Exchange regarding Appointment of Mr. Ashish Mukkirwar as Chief Financial Officer of the company w.e.f. May 23, 2026.
Jubilant Pharmova Limited has informed the Exchange regarding Outcome of Board Meeting held on May 22, 2026.
Jubilant Pharmova Limited has informed the Exchange regarding Outcome of Board Meeting held on May 22, 2026.
Jubilant Pharmova Limited has informed the Exchange that Record date for the purpose of DI is 24-Jul-2026.
Jubilant Pharmova Limited has informed the Exchange that Board of Directors at its meeting held on May 22, 2026, recommended Final Dividend of Rs. 5 per equity share.
Jubilant Pharmova Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
Jubilant Pharmova Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015
Jubilant Pharmova Limited has informed the Exchange about General Updates
Jubilant Pharmova Limited has informed the Exchange about Copy of Newspaper Publication
Jubilant Pharmova Limited has informed the Exchange regarding a press release dated February 06, 2026, titled "Press Release alongwith Earnings Presentation on the financials and operational performan...
Jubilant Pharmova Limited has submitted to the Exchange, the financial results for the period ended December 31, 2025.